EUVIMED · CrossrefJournal
Expert Review of Anticancer Therapy
ISSN 1473-7140 · Informa UK Limited
Latest articles
Darolutamide in Spain: a multicenter review of real-world clinical practice in nmCRPC and mHSPC
Precision medicine in genitourinary malignancies: integrating molecular profiling into clinical practice
From collision to conversion, the molecular renaissance of uterine carcinosarcoma in the era of antibody-drug conjugates: a scoping review
Evaluating vorasidenib in the treatment of IDH1-mutant or IDH2-mutant low-grade gliomas
Biological state–guided oncology: a framework for dynamic precision cancer care through oncological state transitions
Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies
TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome
Survivorship in gynecological cancers: addressing psychosocial and physical challenges
The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma
Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine
The dual role of Schlafen11 in brain tumors: Jekyll and Hyde
Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection
Immune checkpoint inhibitors in people living with HIV and cancer: a Kaplan–Meier-derived individual patient data meta-analysis
The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence
An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches
Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology – a narrative review
Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity
Uveal melanoma: innovations in therapy, prognosis, and imaging
Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications
Antibody–drug conjugates: a practical review on clinical management of toxicities
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
AA amyloidosis as a renal immune-related adverse event of immune checkpoint inhibitors: mechanisms, diagnosis, and management
Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations
The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas
Radiotheranostics in solid tumors: focus on radiopharmaceutical therapy and clinical challenges
ESMO 2025 and new therapies in breast cancer: does society always benefit?
EUVIMED